Objective:

To report a case of suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS) following treatment with adebrelimab in a patient with intrahepatic cholangiocarcinoma.

Approach:

Key Findings:

• The patient experienced rapid onset of severe symptoms, including chest tightness and muscle weakness, 3 days after the second cycle of adebrelimab.
• Laboratory tests indicated significant myocardial injury, with elevated markers such as high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide.
• Despite treatment efforts, the patient succumbed to cardiac arrest on day 9 after the onset of symptoms.

Interpretation:

The case highlights the rapid progression and poor prognosis associated with adebrelimab-induced IM3OS, emphasizing the need for early recognition and aggressive management.

Limitations:

• The case study is based on a single patient, which limits the generalizability of the findings to a broader population.
• Clinical characteristics and optimal management strategies for IM3OS remain poorly defined and require further investigation.

Conclusion:

This case underscores the critical importance of early detection and multidisciplinary intervention in managing severe immune-related adverse events associated with immune checkpoint inhibitors.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.